OncoSec Medical, Inc. (ONCS) Starts Presentation at 4th Annual LD Micro Conference

OncoSec Medical, Inc. (OTC: ONCS) designs and develops novel cancer therapeutic products. The company’s products combine proprietary delivery technology with a novel DNA-based immunotherapeutics, known as OMS ElectroOncology. OncoSec’s clinical programs include: the NeoPulse approach, which is in clinical trials for the treatment of recurrent head, neck and breast cancer; and three clinical trials assessing the cancer-destroying and tissue-sparing properties of the ImmunoPulse technology. For more information, visit the company’s website at www.oncosec.com.